For all the attention on U.S.-China AI competition, new studies point to China’s rapid rise in biotechnology, especially for ...

A dual-track approach has gained momentum for biotech companies as capital markets remain volatile and acquirers become more ...

Rapt Therapeutics has conducted its second round of layoffs in just under a year, continuing a period of upheaval following ...

Job cuts at home-grown pharma companies like Arvinas and RallyBio and federal policies challenge CT biotech 'ecosystem' that ...

Axsome Therapeutics is slowly establishing itself as a notable player in the biotech industry. So, despite its shares crushing the market over the past three years, it's not too late to buy the stock.

That is raising alarms in Massachusetts, where the biotech industry depends heavily on imported lab equipment, chemicals, and specialized components, many of which originate in China and Europe. “New ...

You will hear about ways they are defying the odds to churn out clinical data that may finally provide the industry with a ladder out. Watch now. The rumors of biotech’s return have been greatly ...

You can get in touch with Amanda by emailing [email protected]. Biotech giant Regeneron announced Monday that it would acquire DNA testing company 23andMe for $256 million following a ...

Pharmaceutical maker Regeneron announced Monday it will buy genetic testing company 23andMe for $256 million following a bankruptcy auction. Regeneron said it will acquire 23andMe’s genomics ...

(AP Photo/Barbara Ortutay, File) Updated [hour]:[minute] [AMPM] [timezone], [monthFull] [day], [year] Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months ...

Biotechnology company Regeneron will acquire 23andMe out of bankruptcy for $256 million, with a plan to keep the DNA-testing company running without interruption and uphold its privacy-protection ...